[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study evaluating the test product, lacosamide granules (strength: 1 g: 0.1 g), and the reference product, lacosamide dry syrup (Vimpat®) in healthy adult participants under the fasting state
主要试验目的:研究空腹状态下单次口服受试制剂拉考沙胺颗粒(规格:1 g: 0.1 g)与参比制剂拉考沙胺干糖浆(Vimpat® ,规格:10%;UCB日本株式会社生产)在健康参与者体内的药代动力学特征,评价空腹状态口服两种制剂的生物等效性。
次要试验目的:研究受试制剂拉考沙胺颗粒(规格:1 g: 0.1 g)和参比制剂拉考沙胺干糖浆(Vimpat® )在健康参与者中的安全性。
[Translation] The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation lacosamide granules (specifications: 1 g: 0.1 g) and the reference preparation lacosamide dry syrup (Vimpat®, specification: 10%; produced by UCB Japan Co., Ltd.) in healthy participants after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions.
The secondary purpose of the study is to study the safety of the test preparation lacosamide granules (specifications: 1 g: 0.1 g) and the reference preparation lacosamide dry syrup (Vimpat®) in healthy participants.